157 related articles for article (PubMed ID: 36326247)
1. Clinical Outcome with Standard Regimen plus Clofazimine or Moxifloxacin in Cavitary Mycobacterium avium Complex Pulmonary Disease.
Park YE; Chong YP; Lee HJ; Shim TS; Jo KW
Antimicrob Agents Chemother; 2022 Dec; 66(12):e0052822. PubMed ID: 36326247
[TBL] [Abstract][Full Text] [Related]
2. Treatment Outcomes of Cavitary Nodular Bronchiectatic-Type Mycobacterium avium Complex Pulmonary Disease.
Chae G; Park YE; Chong YP; Lee HJ; Shim TS; Jo KW
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0226121. PubMed ID: 35950842
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Treatment Outcomes of Cavitary Mycobacterium avium Complex Pulmonary Disease with Streptomycin or Amikacin Use.
Kim SM; Chong YP; Lee HJ; Shim TS; Jo KW
Microbiol Spectr; 2023 Jun; 11(3):e0474122. PubMed ID: 37022189
[TBL] [Abstract][Full Text] [Related]
4. Treatment outcomes of refractory MAC pulmonary disease treated with drugs with unclear efficacy.
Jo KW; Kim S; Lee JY; Lee SD; Kim WS; Kim DS; Shim TS
J Infect Chemother; 2014 Oct; 20(10):602-6. PubMed ID: 24981714
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Fluoroquinolones as Substitutes for Ethambutol or Rifampin in the Treatment of Mycobacterium avium Complex Pulmonary Disease According to Radiologic Types.
Lee JH; Park YE; Chong YP; Shim TS; Jo KW
Antimicrob Agents Chemother; 2022 Feb; 66(2):e0152221. PubMed ID: 34930036
[TBL] [Abstract][Full Text] [Related]
6. Comparison of treatment outcomes between intermittent and daily regimens in non-cavitary nodular bronchiectatic-type
Jung J; Chong YP; Lee HJ; Shim TS; Jo K-W
Antimicrob Agents Chemother; 2023 Nov; 67(11):e0100323. PubMed ID: 37843254
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of clofazimine-containing regimens for treatment of Mycobacterium avium complex-pulmonary disease in patients unsuitable for standard treatment regimen.
Bao S; Chen S; Zheng J; Ma J; Yang J; Huang H; Duan H
Int J Antimicrob Agents; 2024 Feb; 63(2):107061. PubMed ID: 38103753
[TBL] [Abstract][Full Text] [Related]
8. The natural history of non-cavitary nodular bronchiectatic Mycobacterium avium complex lung disease.
Kwon BS; Lee JH; Koh Y; Kim WS; Song JW; Oh YM; Lee SD; Lee SW; Lee JS; Lim CM; Choi CM; Huh JW; Hong SB; Shim TS; Jo KW
Respir Med; 2019 Apr; 150():45-50. PubMed ID: 30961950
[TBL] [Abstract][Full Text] [Related]
9. Neutrophil-Lymphocyte Ratio and Monocyte-Lymphocyte Ratio According to the Radiologic Severity of
Kim MA; Park YE; Chong YP; Shim TS; Jo KW
J Korean Med Sci; 2022 Oct; 37(40):e292. PubMed ID: 36254530
[TBL] [Abstract][Full Text] [Related]
10. Moxifloxacin resistance and genotyping of Mycobacterium avium and Mycobacterium intracellulare isolates in Japan.
Yamaba Y; Ito Y; Suzuki K; Kikuchi T; Ogawa K; Fujiuchi S; Hasegawa N; Kurashima A; Higuchi T; Uchiya KI; Watanabe A; Niimi A
J Infect Chemother; 2019 Dec; 25(12):995-1000. PubMed ID: 31239192
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of aminoglycosides, clofazimine, d-cycloserine and dapsone against 83 Mycobacterium avium complex clinical isolates.
Huang CC; Wu MF; Chen HC; Huang WC
J Microbiol Immunol Infect; 2018 Oct; 51(5):636-643. PubMed ID: 28705770
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Mycobacterium avium Complex Pulmonary Disease: When Should I Treat and What Therapy Should I Start?
Nguyen MH; Daley CL
Clin Chest Med; 2023 Dec; 44(4):771-783. PubMed ID: 37890915
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of Clofazimine as an Alternative for Rifampicin in Mycobacterium avium Complex Pulmonary Disease Treatment: Outcomes of a Randomized Trial.
Zweijpfenning SMH; Aarnoutse R; Boeree MJ; Magis-Escurra C; Stemkens R; Geurts B; van Ingen J; Hoefsloot W
Chest; 2024 May; 165(5):1082-1092. PubMed ID: 38040054
[TBL] [Abstract][Full Text] [Related]
14. Association Between Duration of Aminoglycoside Treatment and Outcome of Cavitary Mycobacterium avium Complex Lung Disease.
Kim OH; Kwon BS; Han M; Koh Y; Kim WS; Song JW; Oh YM; Lee SD; Lee SW; Lee JS; Lim CM; Choi CM; Huh JW; Hong SB; Shim TS; Jo KW
Clin Infect Dis; 2019 May; 68(11):1870-1876. PubMed ID: 30239615
[TBL] [Abstract][Full Text] [Related]
15. A novel ceftazidime/avibactam, rifabutin, tedizolid and moxifloxacin (CARTM) regimen for pulmonary Mycobacterium avium disease.
Deshpande D; Srivastava S; Pasipanodya JG; Lee PS; Gumbo T
J Antimicrob Chemother; 2017 Sep; 72(suppl_2):i48-i53. PubMed ID: 28922809
[TBL] [Abstract][Full Text] [Related]
16. Clofazimine as a substitute for rifampicin improves efficacy of
Salillas S; Raaijmakers J; Aarnoutse RE; Svensson EM; Asouit K; van den Hombergh E; Te Brake L; Stemkens R; Wertheim HFL; Hoefsloot W; van Ingen J
Antimicrob Agents Chemother; 2024 Mar; 68(3):e0115723. PubMed ID: 38259101
[No Abstract] [Full Text] [Related]
17. Efficacy and safety of intermittent maintenance therapy after successful treatment of Mycobacterium avium complex lung disease.
Asakura T; Nakagawa T; Suzuki S; Namkoong H; Morimoto K; Ishii M; Kurashima A; Betsuyaku T; Ogawa K; Hasegawa N;
J Infect Chemother; 2019 Mar; 25(3):218-221. PubMed ID: 30172726
[TBL] [Abstract][Full Text] [Related]
18. Microbiological Persistence in Patients With Mycobacterium avium Complex Lung Disease: The Predictors and the Impact on Radiographic Progression.
Pan SW; Shu CC; Feng JY; Wang JY; Chan YJ; Yu CJ; Su WJ
Clin Infect Dis; 2017 Sep; 65(6):927-934. PubMed ID: 28541556
[TBL] [Abstract][Full Text] [Related]
19. Factors that affect sputum conversion and treatment outcome in patients with Mycobacterium avium-intracellulare complex pulmonary disease.
Ye JJ; Wu TS; Chiang PC; Lee MH
J Microbiol Immunol Infect; 2007 Aug; 40(4):342-8. PubMed ID: 17712469
[TBL] [Abstract][Full Text] [Related]
20. Long-term Follow-up of Mycobacterium avium Complex Lung Disease in Patients Treated With Regimens Including Clofazimine and/or Rifampin.
Jarand J; Davis JP; Cowie RL; Field SK; Fisher DA
Chest; 2016 May; 149(5):1285-93. PubMed ID: 26513209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
